Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial of Doxycycline 50 mg or 100 mg Daily for the Prevention of Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy

NCT03448731 is registered in ClinicalTrials.gov with Fundacion CRIS de Investigación para Vencer el Cáncer as lead sponsor.

NCT NCT03448731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03448731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial of Doxycycline 50 mg or 100 mg Daily for the Prevention of Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy
Lead sponsor
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase
Phase 2
Overall status
Completed
Start date
May 10, 2018
Completion date
April 6, 2020
Enrollment
34 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

skin toxicity